In primary CD34+ AML cells, the response to ETC complex II inhibition was heterogeneous (Fig. 2c), whereby FLT3-ITD+ AMLs were within the most sensitive group (Fig. 2d). This evidence concerns the gene CD34 and acute myeloid leukemia.